University of San Diego

Digital USD
Doctor of Nursing Practice Final Manuscripts

Theses and Dissertations

Spring 5-25-2019

Shingles Vaccine: Identifying high risk groups in the IBD clinic
setting
Crystal Barajas
University of San Diego, cbarajas@sandiego.edu

Follow this and additional works at: https://digital.sandiego.edu/dnp
Part of the Digestive System Diseases Commons, and the Nursing Commons

Digital USD Citation
Barajas, Crystal, "Shingles Vaccine: Identifying high risk groups in the IBD clinic setting" (2019). Doctor of
Nursing Practice Final Manuscripts. 97.
https://digital.sandiego.edu/dnp/97

This Doctor of Nursing Practice Final Manuscript is brought to you for free and open access by the Theses and
Dissertations at Digital USD. It has been accepted for inclusion in Doctor of Nursing Practice Final Manuscripts by
an authorized administrator of Digital USD. For more information, please contact digital@sandiego.edu.

“Shingles Vaccine: Identifying high risk groups in the IBD clinic setting”
UNIVERSITY OF SAN DIEGO
Hahn School of Nursing and Health Science

DOCTOR OF NURSING PRACTICE PORTFOLIO
by
Crystal Barajas, BSN, RN, PHN, DNPc

A Portfolio presented to the
FACULTY OF THE HAHN SCHOOL OF NURSING AND HEALTH SCIENCE
UNIVERSITY OF SAN DIEGO

In partial fulfillment of the requirements for the degree
DOCTOR OF NURSING PRACTICE
May 2019

2
Running head: SHINGLES VACCINE: HIGH RISK GROUPS IN IBD

Abstract

Title: Shingles Vaccine: Identifying high risk groups in the IBD clinic setting
Background: The Inflammatory Bowel Disease (IBD) population is an immunocompromised
patient population who is at risk for Herpes Zoster (HZ) due to their medication regimen, which
further compromises their immune system. It can be difficult for patients to receive appropriate
preventative health maintenance measures due to patients’ fears, primary care providers’ lack of
knowledge, and gastroenterologists not addressing what may be considered primary care topics.
Furthermore, evidence demonstrates that IBD patients have low vaccination rates despite
insurance coverage.
Purpose of Project: (a) To increase awareness of the importance of Shingrix in the Inflammatory
Bowel Disease population (over 50 years old); (b) To increase Shingrix vaccination orders by
5% in a two-month period.
EBP Model/Frameworks: The ACE Star model was used to guide this project.
Evidenced-Based Interventions: A PowerPoint presentation will be utilized to educate IBD
healthcare providers on the newest evidence regarding high risk groups for shingles and
Shingrix. In addition, posters will be located in every patient room for patient education on
Shingrix.
Evaluation/Results: No significant difference was found in vaccination rates between pre-and
post-project implementation of patient posters and staff educational PowerPoint. Limitations
included small patient sample size in post implementation.
Implication for Practice: Most insurance plans now cover Shingrix for patients aged 50 years
and older. Spreading awareness of the importance of this vaccination will aid in increasing low
numbers of vaccination rates in the IBD population.
Conclusion: The new Shingrix vaccine is not a live vaccine, therefore can be administered to
immunocompromised patients, including those patients who have received the previous shingles
vaccine, Zostavax. It is essential to assess health maintenance, including vaccines needed, at
patients’ initial visit.
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Shingles Vaccine: Identifying High Risk Groups in the IBD Clinic Setting
Vaccination rates among the inflammatory bowel disease patient population continue to
be low despite evidence exposing this population is at an increased risk for contracting illnesses
due to the disease process and the treatment of immunosuppressive therapies (Gisbert &
Chapparo, 2013). It Historically, it has been advised to avoid live vaccines in this patient
population, but now with the newly developed Shingrix vaccine, an attenuated vaccine, this adds
to the list of recommended vaccines whether on or off immunosuppressive therapy. Another
issue with the older version of the shingles vaccine, the Zostavax, was that it was recommended
and covered by most insurances after the age of 60; this new vaccine, Shingrix, is recommended
and covered by most insurances for patients over the age of 50. Regardless of whether the patient
has received the Zostavax in the past, the Shingrix is recommended.
Background and Significance
The Inflammatory Bowel Disease (IBD) population is an immunocompromised patient
population who is at further risk for Herpes Zoster (HZ) due to their treatment regimen. In a
review article of previous research, it is hypothesized that the features of IBD, in combination
with immunosuppressive therapy, could result in lower response rates of vaccinations, thus
making it imperative to give vaccinations before implementing therapy if possible (Gisbert &
Chaparro, 2013). Patients at highest risk for acquiring Herpes Zoster include those on triple
immunosuppressive therapy including corticosteroids, disease-modifying antirheumatic drugs
(DMARDs), and biologics. Studies show it can be difficult for patients to receive appropriate
preventative health maintenance measures due to patients’ fears, primary care providers’ lack of
knowledge, and gastroenterologists not addressing primary care topics (Reich, Wasan, &
Farraye, 2016). Ways to close these gaps in care would be to assess health maintenance at an
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initial gastroenterologist visit and send primary care provider recommendations for vaccine
administration. Furthermore, evidence demonstrates that IBD patients have low vaccination rates
despite insurance coverage (Reich et al., 2016).
Purpose of Project
The purpose of this evidence-based project was to increase awareness of the importance
of the Shingrix vaccine in the inflammatory bowel disease population, over the age of 50. The
goal was to increase vaccination orders and recommendation rates for this high-risk group by 5%
in a 2-month period. A PowerPoint presentation was utilized to educate IBD healthcare providers
on the crucial information and literature findings. In addition, posters, which included side
effects of the vaccine and pricing information, were located in every patient room for patient
education. A chart review was completed on all patients over the age of 50, for the 2 months
following PowerPoint and poster implementation, to check for number of recommendations and
orders placed by healthcare providers in this inflammatory bowel disease center in the
metropolitan area of San Diego, California.
Literature Review
While conducting this literature review, the databases Cochrane, CINAHL, and Pub Med
were used. Key words such as: inflammatory bowel disease, IBD, Crohn’s Disease, Ulcerative
Colitis, Shingrix, Zostavax, inflammatory bowel disease plus shingles, inflammatory bowel
disease plus vaccines, and immunosuppressive therapy were searched. As this evidence-based
project progressed, more articles were found because the Shingrix vaccine has only been
approved as of October 2017, therefore this topic is slowly surfacing new research findings and
journal articles.
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Studies such as one done in Korea (Soh et al., 2019), have looked at the risk of acquiring
shingles in the inflammatory bowel disease patient population. The retrospective study looked at
30,100 patients with IBD and matched them by age and gender to 150,500 non-IBD patients. The
information was gathered between 2010 to 2013 from patients in Korea. The results showed an
increase risk was evident in patients with inflammatory bowel diseases, especially in those who
were younger and were otherwise healthy without metabolic comorbidities (Soh et al., 2019).
In the collection of randomized controlled trial data by Colombel (2018), there was an
increased risk of HZ for non-TNFi agents overall (abetimus, interleukin-1 receptor antagonist,
abatacept, tocilizumab, ustekinumab, sifalimumab, and natalizumab data combined) when
compared to TNFi agents (etanercept, adalimumab, Anbainuo, infliximab, certolizumab pegol,
and golimumab data combined). Similarly, risks of HZ have been notable for Crohn’s disease
and ulcerative colitis patients receiving thiopurine therapy (Colombel et al., 2018). Furthermore,
after biologics such as infliximab, adalimumab, or certolizumab pegol, or combination (both
thiopurine and biologic) therapies were administered, a slight increase in risk of HZ were
visualized for patients with ulcerative colitis in comparison to Crohn’s disease. Additionally, in
the meta-analysis from Colombel (2018), JAK inhibitors, as well as tofacitinib, have been
associated with HZ risk in patients. It is hypothesized that the key inflammatory cytokines and
the regulation of the immune response could put the patient at risk for HZ. In this same metaanalysis, a dose-dependent risk for HZ was observed with tofacitinib, with most cases being noncomplicated, mild to moderate in severity, and manageable with antiviral medication. Therefore,
tofacitinib can be safely continued after an event of shingles. In fact, most patients in the
tofacitinib clinical programs were able to continue tofacitinib treatment during their shingles
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event, with a small portion of patients temporarily discontinuing tofacitinib and resuming after
antiviral therapy (Colombel, 2018).
In a meta-analysis inclusive of 57 studies out of 4,225 articles screened, Marra, Lo,
Kalashnika, and Richardson (2016) looked at the correlation between the risk of HZ and
immunosuppression therapy. Evidence showed an increased risk of shingles in
immunocompromised patients taking biologics, particularly non-TNF-α blockers. An increased
shingles risk was also seen in patients taking corticosteroids and nbDMARDs. Biologics and
DMARDS are used as treatment for inflammatory bowel disease patients. Biological agents
differ in their potency when targeting opportunistic infections, and investigating newer agents
with different therapeutic actions than the traditional TNF-α inhibitors is essential.
A higher incidence of HZ cases were detected in patients who were on the medication
tofacitinib for ulcerative colitis management (Winthrop et al., 2018). The authors observed that
amongst older individuals, Asian patients, and those with prior TNFi use, who were taking 10mg
of tofacitinib twice daily, and those with initial corticosteroid use, had higher incidences of HZ
outbreaks. Age and prior TNFi failure were acknowledged as independent risk factors in
ulcerative colitis patients who acquired HZ while using tofacitinib. Reports by Winthrop et al.
(2016) and Winthrop et al. (2018) of patients taking tofacitinib and baricitinib for rheumatoid
arthritis yielded a 1.5- to 2-fold increase in risk in HZ within some Asian countries compared
with North American and European regions.
The higher incidences in Asia for patients taking JAK inhibitors is unknown (Winthrop et
al., 2018). One possible reason for the increased risk of HZ in rheumatoid arthritis patients taking
tofacitinib is from a genetic analysis that identified two single nucleotide polymorphisms (SNPs)
that presented an increased risk within Japanese and Korean populations (Winthrop et al., 2018).
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The SNPs were intermittently present and were reflected in only a small percentage of the
increased incidence noted with the patient sample. In this study, there was one case of
encephalitis and nearly all prior reported cases with tofacitinib, and other JAK inhibitors have
involved skin or ocular diseases only (Winthrop et al., 2016).
The mechanism of action by which tofacitinib or other JAK inhibitors increase the risk of
HZ is unclear. In conclusion, with the data gathered by both Winthrop (2016; 2018) studies, the
discussion points included the importance of vaccinations for HZ risk management and the
benefits to all patients with immune-mediated diseases who receive treatment, principally those
using JAK inhibitors. One recommendation concluded that when HZ occurs, antiviral therapy
should be considered and tofacitinib temporarily stopped until resolution (Winthrop et al., 2018).
At the University of Manitoba, an IBD Epidemiology Database was used to identify cases
of inflammatory bowel disease and controls from 1984 to 2016 who were diagnosed with Herpes
Zoster before and after 2009, which was when the shingles vaccine was introduced (Nugent,
Singh, Targownik, & Bernstein, 2018). The university wanted to look at the rates of vaccinations
for HZ in patients older than age 50. They also investigated if there were any correlations among
the patients that received the vaccinations. The data demonstrated the control patients were more
likely to get the HZ vaccine than those with IBD. Patients newly diagnosed with IBD who were
of higher socioeconomic status also had higher rates of the HZ vaccine. This systematic review
also noted the incidence of having HZ infections in persons with chronic immune-mediated
diseases receiving biologics was 60% to 70% more likely than controls (Nugent et al., 2018).
Studies such as the one by Hechter, Tartof, Jacobsen, Smith, & Tseng (2013) viewed data
from Kaiser Permanente Southern California and looked at racial disparities and Herpes Zoster
vaccine rates. The data revealed that within the sample size of 819,466 patients, coverage rate
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was higher in patients between that ages of 65 and 74 years and who were non-Hispanic White
females. Coverage among non-Hispanic Whites and Asian/Pacific Islanders was similar and
higher than the coverage for African-American/African and Hispanics (Hechter et al., 2013). The
statistics on this study were collected to look at Herpes Zoster vaccination numbers and coverage
regardless of the presence or absence of disease. These findings, therefore, are not specific to
IBD, but important to keep in mind, since vaccination rates are already low in the IBD
population and for African-Americans/Africans and Hispanics.
In a retrospective study, which included two cohorts of 67,920 participants total, the
United States Department of Veterans Affairs healthcare system compared the overall risk of
acquiring Herpes Zoster if patients were taking immunosuppressant therapy (Khan et al., 2018).
Numbers were collected from patient records between January 1, 2000 and June 30, 2016. The
results displayed that when compared to patients who did not have IBD, patients with ulcerative
colitis (UC) and Crohn’s disease (CD) had a significantly higher risk of Herpes Zoster infection.
Additionally, IBD patients who were treated with 5- aminosalicylate acid (5-ASA) treatment
alone also had an amplified risk of acquiring herpes zoster. When comparing the patients, who
were treated with 5-ASA alone, there was also an increased risk for those patients on thiopurines
or a combination therapy of thiopurines and TNF antagonists. TNF antagonist therapy alone did
not demonstrate an increased risk of Herpes Zoster (Khan et al., 2018). Even more intriguing,
this study exposed that vaccination rates nationwide for Herpes Zoster, in the IBD population
without insurance constraints remained tremendously low.
Theoretical Model
For this evidenced-based project, the ACE Star Model of Knowledge Transformation
(Stevens, 2013) was used to carry out implementation of a quality improvement project that was
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targeted at increasing Shingrix vaccination rates. There are five points on this model titled:
discovery research, evidence summary, translation into guidelines, practice integration, and
process/outcome evaluation. This model was chosen to guide this project due to its simplicity
and for being applicable to evidence-based practice projects.
Under the first point, discovery research, a quality improvement project was discussed
with the facility’s nurse practitioner and medical director. A problem was identified which was
the low Herpes Zoster vaccination rates in the immunocompromised population. The age range
of 50 years and older was targeted because the Shingrix vaccine is approved for use in patients
50 years and older. This was also the step in which databases such as PubMed, CINAHL, and
Cochrane were used to collect evidence on the importance of the shingles vaccine in the
inflammatory bowel disease population.
The second point was the evidence summary, which included a literature review that was
incorporated into the staff education PowerPoint slide deck. The literature was narrowed down to
nine articles that included information from medications that caused immunosuppression, to
pathology of the immunosuppressive disease, low vaccination rates in the IBD population, and
racial disparities in vaccination numbers of the Herpes Zoster vaccine.
The third point was translation into guidelines. The Shingrix vaccination guidelines and
recommendation of the Centers for Disease Control and Prevention (CDC) were used to guide
the educational portion and recommendations listed in the staff educational PowerPoint. It was
also recommended that after discussing the vaccine with patients, an order for the vaccine be
placed or a recommendation note would be written in the patients’ plan-of-care.
The fourth point was that of practice integration. On December 19, 2018, the project was
piloted for a total of two months. The posters with vaccine information were placed in patient
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rooms and the staff education PowerPoint was sent via email for providers to read at their
convenience in a one week period. Providers were then asked to send an email back stating they
had reviewed the PowerPoint.
The final fifth point was the process/outcome evaluation. The project concluded on
February 19, 2019. Data was collected on pre-and post-PowerPoint and poster implementation.
The data collected included demographic information as well as pre-and post-orders and
recommendation numbers of both Shingrix and Zostavax rates.
Practice Change Process
The nurse practitioner at the inflammatory bowel disease center at a large facility in San
Diego, California was approached by the Doctor of Nursing Practice student regarding the needs
of the facility. After further discussion, the student and nurse practitioner agreed on a change-ofpractice plan that would be simple enough for providers to incorporate and an educational quality
improvement project that would bring awareness to the latest research on the shingles vaccine
which had been approved for patients aged 50 years and older, the year prior on October 2017.
Both the student and nurse practitioner presented their proposal to the medical director of
gastroenterology and he approved both components of the project: emailing an educational
PowerPoint presentation and posting information flyers in patient rooms to increase awareness of
the importance of the shingles vaccine, thus encouraging the increase in numbers of Shingrix
vaccination rates in this vulnerable population.
After the PowerPoint slide deck was emailed to staff in the inflammatory bowel disease
department, data was collected for the two months prior to project implementation and two
months post- project implementation. Data was collected on patients’ demographics, if they were
taking immunosuppressive therapy, if they had Zostavax in the past, and if they had any orders
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or recommendations placed in their charts for the Shingrix vaccine. The quality improvement
evidence-based project goal was to increase awareness of the importance of Shingrix in the IBD
population (over 50 years old) and increase vaccination rates for this high-risk group by 5% in a
two-month period.
Cost/Benefit Analysis
Limited information was available on the cost benefit of the Shingrix vaccine for the
United States at the time the literature review was completed. This is due to the relatively new
information that continues to be studied and submitted for publication. One retrospective study
from Canada showed that in 2011-2012, the average cost of an episode of Herpes Zoster was
$127.34 (Friesen, Chateau, Falk, Alessi-Severini, & Bugden, 2017). This price included pain
medications and antivirals. For Herpes Zoster that led to post-herpetic neuralgia, the drug cost
was approximately $635, including again both antivirals and pain medications; with more
spending on pain medications due to long term effects. It is estimated that the Shingrix vaccine
costs approximately $244 per dose in Canada. As future studies and data are collected in the
United States, there will be better estimates of San Diego prices for episodes of Herpes Zoster,
episodes leading to post-herpetic neuralgia and, cost benefit analyses specific to medical costs in
this country. Today in San Diego, the Shingrix vaccine ranges from $150 to $190 per dose
depending on which pharmacy is used and under which insurance plan. The complete series of
this vaccine is two doses, therefore this project also emphasized for providers the importance of
using the vaccine company as a resource for information on reimbursement forms as well as
GoodRx.com when recommending the vaccine and ordering it for patients.
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Results
The pre-implementation group consisted of 44 patients and the post-implementation
group consisted of 25 patients. Of the 69 patients in total, 45% were female and 55% were male
(Figure 1). The patient sample size was further broken down by age groups: 23 patients were in
their 50s, 30 patients in their 60s, 11 patients in their 70s, and five patients in their 80s (Figure
2). When looking at how many patients were on immunosuppressive therapy at the time, 11% of
the pre-implementation group were not on immunosuppressive therapy compared to the postimplementation group in which 16% of patients were not on immunosuppressive therapy (Figure
3). The remainder of the sample size was on immunosuppressive therapy, bringing the
percentages to 88.6% in the pre-implementation group and 84% in the post-implementation
group. Lastly, the data exposed order and recommendation rates in both the pre-and postimplementation rates to be 18.9% and 31.6% respectively (Figure 4). The second sample size,
however, was not large enough to make the difference significant.
The patient sample size was acquired by counting all the patients over the age of 50 who
were seen in the two months before implementing the educational PowerPoint and flyers in the
patient rooms, and all the patients over 50 years old seen post-project implementation. None of
the patients in the sample size were seen twice in those two time frames. Data was collected by
manually reviewing the patients’ charts and analyzing the orders placed, medication orders,
immunization records, and the clinic visit note recommendations and plan of care. There was no
significant difference in referral numbers pre-and post-implementation of this evidence-based
quality improvement project when reviewing chi-square data.
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Figure 1. Gender of the Sample Size

Figure 2. Age of the Sample Size
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Figure 3. Patients on Immunosuppressive Therapy

Figure 4. Number of Shingrix Orders and Recommendations Placed

Implications for Practice
Most insurance plans now cover Shingrix for patients aged 50 years and older. Spreading
awareness of the importance of vaccination will aid in increasing our low numbers of vaccination
rates in the IBD population who are especially vulnerable to acquiring the HZ infection. More
importantly, HZ can be prevented, so it will be imperative to assess health maintenance, which
includes vaccines needed at initial gastroenterology and primary care visits. As a healthcare
provider, one can also refer the patient to a pharmacy to receive Shingrix or to their primary care
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provider and ask that the patient ensure their immunization records are up to date in the
gastroenterology office. Another recommendation would be to ask patients if they have any
questions or concerns about the vaccine when recommending it.
Discussion
When discussing the results and limitations with the medical director of the facility and
University of San Diego faculty mentor, all concurred that low vaccination rates for Shingrix in
the IBD population are a concern. Especially, because patients who had the older live shingles
vaccine can and should get the newer shingles vaccine because of its higher efficacy rate in
preventing Herpes Zoster.
Limitations to reaching the projected goal of significantly increasing Shingrix vaccination
rates in this vulnerable population were that the provider whose schedule was being monitored
for data collection changed in the last month, or halfway through project implementation.
Another possible limitation could have been the providers viewing the PowerPoint on their own
time instead of scheduling a group in-service meeting for everyone to get the information and
lecture at the same time. An extension to this project would be to create an alert on the electronic
medical record system, reminding providers to order the Shingrix vaccine for patients over the
age of 50 years old. Another suggestion by the medical director of the inflammatory bowel
disease center was to create a protocol for staff, including nursing staff, to assist with the
adherence to Shingrix.
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